8-K: Protara Therapeutics Announces Positive Phase 2 Interim Results and First Quarter 2025 Financial Results

Protara Therapeutics reports positive interim results from its ADVANCED-2 trial of TARA-002 in NMIBC and provides a business update alongside its Q1 2025 financial results.

Summary

• Protara Therapeutics announced its first quarter 2025 financial results and provided a business update on May 8, 2025.
• The company reported positive interim results from the Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC patients.
• A complete response rate at any time of 100% (5/5) and 67% (2/3) at 12 months was demonstrated in BCG-Unresponsive patients.
• In the BCG-Nave cohort, TARA-002 showed a complete response rate at any time of 76% (16/21) and a 43% (3/7) complete response rate at 12 months.
• The company expects to announce interim results from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025.
• Dosing of the first patient in the THRIVE-3 registrational trial of IV Choline Chloride is expected in Q3 2025.
• Protara strengthened its leadership team with the appointments of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, and Shane Williams, Ph.D., as VP, Head of Human Resources, Chief People Officer.
• As of March 31, 2025, the company had $158 million in cash, cash equivalents, and investments, which is expected to fund operations into 2027.
• The net loss for the first quarter of 2025 was $11.9 million, or $0.29 per share, compared to a net loss of $11.1 million, or $0.97 per share, for the same period in 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical trial results, a strong cash position, and strategic leadership appointments. While there are net losses, the overall tone is optimistic about the company's future prospects.

Positives

• TARA-002 showed promising complete response rates in both BCG-Unresponsive and BCG-Nave NMIBC patients.
• The company has a strong cash position of $158 million, expected to fund operations into 2027.
• The leadership team has been strengthened with the addition of a new Chief Medical Officer and VP, Head of Human Resources, Chief People Officer.
• Dosing continues to progress in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with macrocystic and mixed cystic LMs and the Company intends to provide an interim update from the trial in the second half of 2025.

Negatives

• The company incurred a net loss of $11.9 million for the first quarter of 2025.
• Research and development expenses increased to $9.1 million from $7.7 million for the prior year period.
• General and administrative expenses increased to $5.0 million from $4.1 million for the prior year period.

Risks

• The company's financial guidance may not be as expected.
• There are risks associated with the company's development programs, including clinical trials and regulatory filings.
• General market conditions and changes in the competitive landscape could impact the company's performance.
• The company's ability to obtain sufficient financing to fund its strategic plans and commercialization efforts is a risk.
• Failure to attract and retain management and key personnel is a risk.

Future Outlook

The company expects its cash, cash equivalents, and investments to be sufficient to fund operations into 2027 and anticipates several exciting data milestones in the coming months.

Management Comments

• We have made significant progress thus far in 2025, notably with the recent presentation of positive interim results from our ADVANCED-2 trial of TARA-002 in BCG-Unresponsive and BCG-Nave patients which demonstrated durable 12-month landmark responses, said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
• We believe TARA-002 is well positioned to make a meaningful difference in the lives of patients with non-muscle invasive bladder cancer (NMIBC).
• In addition to our NMIBC program, we are pleased with the continued progress we have made across our rare disease programs and look forward to several exciting data milestones in the coming months.

Industry Context

Protara's focus on NMIBC and rare diseases aligns with the growing demand for innovative therapies in these areas. The positive results from the ADVANCED-2 trial could position TARA-002 as a potential treatment option for patients with limited alternatives.

Comparison to Industry Standards

• The 100% complete response rate at any time in BCG-Unresponsive NMIBC patients is a strong result compared to existing therapies and other investigational agents in development.
• For example, Merck's Keytruda has shown efficacy in BCG-unresponsive NMIBC, but the complete response rates vary depending on the study population and duration of follow-up.
• Similarly, other companies like CG Oncology are developing oncolytic viruses for NMIBC, and their clinical trial results will provide further context for evaluating TARA-002's potential.
• The development of IV Choline Chloride addresses an unmet need in patients on parenteral support, as there are currently no FDA-approved IV choline formulations.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results and strong cash position.
• Employees may be motivated by the company's progress and strengthened leadership team.
• Patients with NMIBC and LMs may benefit from the development of new treatment options.
• Patients on parenteral support may benefit from the development of IV Choline Chloride.

Next Steps

• Announce interim results from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025.
• Initiate the THRIVE-3 registrational Phase 3 clinical trial for IV Choline Chloride in Q3 2025.
• Provide an update on the design of its planned BCG-Nave registrational trial in the second half of 2025.
• Provide an interim update from the STARBORN-1 trial in the second half of 2025.
• Continue investigating subcutaneous dosing through priming and maintenance combined with intravesical dosing, as well as exploring combination treatment with TARA-002 in NMIBC patients with CIS.

Key Dates

Keywords

TARA-002, NMIBC, IV Choline Chloride, Clinical Trial, Financial Results, Protara Therapeutics, ADVANCED-2, THRIVE-3, Leadership, Cash Position, STARBORN-1, LMs